Literature DB >> 27799395

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.

Marianne Riou1,2,3,4, Andrei Seferian1,2,3, Laurent Savale1,2,3, Marie-Camille Chaumais1,3,5, Christophe Guignabert1,3, Matthieu Canuet4, Pascal Magro6, Delphine Rea7, Olivier Sitbon1,2,3, Xavier Jaïs1,2,3, Marc Humbert1,2,3, David Montani8,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27799395     DOI： 10.1183/13993003.01410-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  11 in total

1.  Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.

Authors:  Julien Mahé; Emilie Patras de Campaigno; Anne-Laure Chené; Jean-Louis Montastruc; Fabien Despas; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2018-08-05       Impact factor: 4.335

2.  Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.

Authors:  Marie-Camille Chaumais; Caroline O'Connell; Laurent Savale; Christophe Guignabert; Frédéric Perros; Xavier Jaïs; Olivier Sitbon; Marc Humbert; David Montani
Journal:  Int J Clin Pharm       Date:  2018-08-13

Review 3.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

4.  iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension.

Authors:  Mingxia Gu; Michele Donato; Minzhe Guo; Neil Wary; Yifei Miao; Shuai Mao; Toshie Saito; Shoichiro Otsuki; Lingli Wang; Rebecca L Harper; Silin Sa; Purvesh Khatri; Marlene Rabinovitch
Journal:  Sci Transl Med       Date:  2021-05-05       Impact factor: 17.956

5.  A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib.

Authors:  Karan Seegobin; Amit Babbar; Jason Ferreira; Brittany Lyons; James Cury; Vandana Seeram
Journal:  Pulm Circ       Date:  2017-10-24       Impact factor: 3.017

6.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 7.  A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.

Authors:  Zahra Nekoukar; Minoo Moghimi; Ebrahim Salehifar
Journal:  Blood Res       Date:  2021-12-31

8.  Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase.

Authors:  Ibuki Takatsuka; Hiroya Hirata; Takumi Takahashi; Satoshi Dohtan; Shinichiro Oka; Nami Sakamoto; Masamitsu Takaba; Miwa Adachi; Tomonari Takemura; Yasuyuki Nagata; Takaaki Ono
Journal:  Leuk Res Rep       Date:  2022-04-19

Review 9.  Differentiating pulmonary hypertension associated with protein kinase inhibitors.

Authors:  Joshua A Jacobs; Eiman Jahangir; John J Ryan
Journal:  Pulm Circ       Date:  2022-05-11       Impact factor: 2.886

10.  Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.

Authors:  Qiuying Selina Liu; Nour Ali Ass'ad; Cecilia Arana Yi
Journal:  Clin Case Rep       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.